Tegafur plus MMC or ACNU in the treatment of advanced gastric cancer-a pilot study
Twenty four cases of advanced gastric cancer were divided into two groups according to the general condition of the patients (PS 0–2 and 3–4), further subdivided into localized abdominal form, liver metastatic form, ascitic form and distant metastatic form. These patients were allocated randomly into Regimen A or B. Regimen A: Tegafur 600 mg daily and Mitomycin C (MMC) 5 mg/m2/1–2 weeks. Regimen B: Tegafur 600 mg daily and ACNU (Nimustine, water-soluble Nitrosourea) 60 mg/week for 2 weeks. After a course of ACNU, it was with drawn for 4 weeks and then resumed again. The response rate of Regimen A was 3/11 (27%), that of Regimen B was 3/13 (23%).
KeywordsGastric Cancer Mitomycin Advanced Gastric Cancer Tegafur Barium Meal
Unable to display preview. Download preview PDF.
- 2.Kimura K, et al. Cooperative study group of phase I study of ACNU. Phase I study of 1-(4-amino-2-methyl-5-pyrimidinyl) methyl-3-(2-chloroethyl)-3-nitrosourea hydrochloride (ACNU). Jap J Clini Oncol 1976; 12(1):33.Google Scholar
- 3.Kubota T, et al. Antitumor effect of 3-(4-amino-2-methyl-5-pyrimidinyl) methyl-1-(2-chloroethyl)-1-nitrosourea (ACNU) on human colon carcinomas transplanted into nude mice. Jap J Clini Oncol 1982; 12(1):33.Google Scholar
- 4.Sasai T, et al. UFT+MMC and UFT+ACNU therapy for advanced gastric cancer. Jap JT Cancer Chemother 1988; 15(1):141.Google Scholar
- 6.Kurihara M, Nakajima T. Chemotherapy for gastric cancer. Tokyo Shinko Igaku Shuppan 1981; 109–158.Google Scholar